U.S. stock market changes! Many Chinese pharmaceutical stocks such as Wanchun Pharmaceutical and Hutchison Pharmaceutical rose

【Pharmaceutical Network Pharmaceutical Stock Market】Wednesday news, U.
S.
stocks changed, some Chinese pharmaceutical stocks rose significantly, individual stocks, as of the early morning of the next day, Wanchun Pharmaceutical rose more than 16%, Huang Pharmaceutical rose more than 8%, Jiuzhou Pharmacy rose nearly 4%, Zhilin Group rose more than 4%, Tianyan Pharmaceutical rose more than 3%.

It is understood that Wanchun Pharmaceutical has performed well recently, rising 17%
against the sector on Monday.
The stock is a clinical-stage global biotechnology company that landed on the NASDAQ market in 2017 and its share price reached $48.
49 per share
at its peak.
It is worth mentioning that previously, after the core product Plinabulin was rejected by the US FDA, Wanchun Pharmaceutical suffered a setback
in the US stock market because its stock price fell below the minimum requirement of $1 per share for 30 consecutive trading days.
Wanchun Pharmaceutical announced on November 23 that it had received a written delisting warning
from NASDAQ on November 18.
It is understood that according to the delisting rules of NASDAQ, from the issuance of the notification letter to May 17, 2023 is the compliance period, if the closing price of Wanchun Pharmaceutical exceeds 1 US dollar per share for 10 consecutive days during this compliance period, Nasdaq can withdraw the delisting warning letter
.
Hutchison Pharmaceutical, which rose more than 8%, was listed
on NASDAQ on March 17, 2016.
On the news, on December 19, Hutchison announced that it began to submit a new drug application for fruquintinib for the treatment of refractory metastatic colorectal cancer to the FDA on a rolling basis, and is expected to complete the application submission in the first half of 2023, and will subsequently submit a new drug application
to the European Medicines Agency (EMA) and the Japanese Agency for Pharmaceuticals and Medical Devices (PMDA).
Data show that fruquintinib is a highly selective oral vascular endothelial growth factor receptor (VEGFR)-1/2/3 inhibitor
.
In phase II and phase III trials, fruquintinib improved progression-free survival (PFS) in patients with advanced non-squamous NSCLC compared with placebo with a controllable
safety profile.
Southwest Securities believes that fruquintinib is about to go to sea, pointing to the global market and maintaining "buying"
.
Jiuzhou Pharmacy rose nearly 4 percent, the first pharmacy retail brand in China to be listed on the NASDAQ in the United States, which was listed
on the NASDAQ in April 2010.
Recently, the US stock market of Jiuzhou Pharmacy has been active, rising significantly continuously, and even rose by more than 50%
during the period.
The analysis believes that the sharp rise in the pharmaceutical stock is mainly related to
the sharp increase in people's demand for drugs after the optimization of epidemic prevention and control.
Recently, drugs and consumables, including Lianhua Qingwen, Tylenol, antigen detection reagents and other items, are all items that are in high demand by the public, and the sharp rise in demand has stimulated the rise in stock prices
.
In addition, Zhilin Group is a pre-clinical stage pharmaceutical company to address unmet medical needs
.
The stock was listed on the NASDAQ Stock Exchange on December 18
, 2018.
On the news, AplinGroup recently announced that the company will issue convertible notes due 2023 with a total principal amount of US$3 million to a limited number of specific investors
.
The planned issuance is unsecured notes convertible into restricted Class A ordinary shares of the Company with a par value of $1.
00 per share for a period of 12 months and a 7% coupon rate at a conversion price of $
1.
20 per share.
It is reported that the Company intends to use the net proceeds primarily to fund the continued research and development of its therapeutic candidates, including SACT-1 and ALS-4, and its liquid biopsy diagnostic program, the commercialization of NativusWell women's health nutrition products, and the Company's daily operations and general use
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.